Company news
Regen Biopharma, Inc. news in 2017
Regen Biopharma, Inc.'s news releases, calls and decks from 2017, newest first.
Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules
December 11, 2017
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
November 27, 2017
Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
November 16, 2017
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
November 8, 2017
Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)
October 30, 2017
Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6
October 23, 2017
Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases
October 16, 2017
Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6
October 3, 2017
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
September 19, 2017
Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6
September 6, 2017
Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics
August 9, 2017
Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators
July 25, 2017
Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint
July 12, 2017
Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases
May 16, 2017
Regen BioPharma, Inc. Identifies Three New Series of Compounds That Activate NR2F6
April 18, 2017
Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6
April 12, 2017
Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis
March 23, 2017
Regen BioPharma Restructures Management Stock Compensation
March 15, 2017
Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.
March 2, 2017
Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators
February 1, 2017